News
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
News
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.
News
ALTA-1L: Brigatinib beats crizotinib for PFS in ALK-positive NSCLC
The ALTA-1L trial showed a 51% reduction in progression-free survival with brigatinib versus crizotinib in ALK-positive NSCLC.
News
Some mutation testing can be useful at CLL diagnosis
CHICAGO –
News
IMPower132 trial: Atezolizumab improves PFS in advanced nonsquamous NSCLC
TORONTO – Atezolizumab as part of first-line and maintenance therapy improves PFS in advanced nonsquamous NSCLC.
News
IMpower133: Atezolizumab plus standard chemotherapy boosted survival in ES-SCLC
Adding atezolizumab to standard first-line ES-SCLC treatment significantly improved overall survival and progression-free survival in the...
News
CDC: Trivalent adjuvanted influenza vaccine aIIV3 safe in elderly adults
ATLANTA – Postlicensure surveillance shows no new or unexpected adverse events with aIIV3 (FLUAD).
News
PCV13 moderately effective in older adults
ATLANTA - As ACIP reevaluates PCV13 for certain older adults, a case-control study shows moderate effectiveness against invasive pneumococcal...
Article
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
News
FDA approves oral dacomitinib for some metastatic NSCLC
The drug has a recommended dose of 45 mg once daily with or without food.
News
PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLC
TORONTO – Updated PACIFIC trial results show that durvalumab provides first major OS, PFS advance for stage III NSCLC in decades.
News
NELSON trial: CT Screening reduces lung cancer deaths
The NELSON trial is the second large-scale trial to show that screening significantly reduces lung cancer mortality.
News
Neoadjuvant combo yields high pathologic response in NSCLC
TORONTO – Neoadjuvant combined chemotherapy and immunotherapy (CT-IO) yielded high pathologic response rates for...